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Abstract: A key challenge for the improvement of clear cell renal cell carcinoma (ccRCC)
management could derive from a deeper characterization of the biology of these neoplasms that
could greatly improve the diagnosis, prognosis and treatment choice. The aim of this study was to
identify specific miRNAs that are deregulated in tumor vs. normal kidney tissues and that could
impact on the biology of ccRCC. To this end we selected four miRNAs (miR-21-5p, miR-210-3p,
miR-185-5p and miR-221-3p) and their expression has been evaluated in a retrospective cohort of
formalin-fixed paraffin-embedded (FFPE) tissues from 20 ccRCC patients who underwent surgical
nephrectomy resection. miR-21-5p and miR-210-3p resulted the most significantly up-regulated
miRNAs in this patient cohort, highlighting these onco-miRNAs as possible relevant players
involved in ccRCC tumorigenesis. Thus, this study reports the identification of specific oncogenic
miRNAs that are altered in ccRCC tissues and suggests that they might be useful biomarkers in
ccRCC management.
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1. Introduction
Renal cell carcinoma (RCC) is a common group of chemotherapy-resistant diseases and
represents 2%–3% of adult malignancies, with the clear cell histotype (ccRCC) accounting for
80%–90% of all RCCs [1]. To date, the incidence of ccRCC has evidently increased and its mortality
rate has reached 40%. Since ccRCC appear to be insensitive to chemotherapy and radiotherapy,
the research of an effective post-operative adjuvant therapies is strongly needed [2].
A key challenge for the improvement of ccRCC management could derive from a deeper
molecular characterization of these neoplasms that could greatly improve the diagnosis, prognosis
and treatment choice [3]. In several tumors, miRNAs expression profile is emerging as a relevant
marker for diagnosis, prognosis and treatment of cancer [4,5]. miRNAs are 22 nucleotides-long
double strand small RNAs, typically excised from 60 to 110 nucleotide RNA precursor structures,
which modulate gene expression generally at post-trascriptional level [6]. In fact, miRNAs show a
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developmental stage- and tissue-specific expression pattern and are present in complex regulatory
circuits to regulate stem cells function, tissue differentiation and maintenance of cell identity
during embryogenesis and adult life [7]. Notably, miRNA activity has also been correlated to the
pathogenesis of cancer, since miRNAs have also been recently identified as a new class of genes with
tumor-suppressor and oncogenic functions [8,9].
To date, a molecular characterization of ccRCC is under investigation and several
high-throughput analyses have been recently performed in order to identify miRNAs putatively
involved in ccRCC tumorigenesis and progression [10–12]. For example, miRNAs signatures are
emerging as correlating with stage, grade and progression in ccRCC and, interestingly, a signature
of 22 miRNAs that significantly correlated with patient survival was also recently described [13,14].
Moreover, specific miRNAs were identified to discern ccRCC from both papillary RCC (pRCC) and
normal tissue [15]. Finally, a role of miRNAs in ccRCC metastatic progression is rapidly emerging as
well [16–19].
Among the miRNAs showing a prognostic value in ccRCC, miR-21 and miR-210 demonstrated
functional relevance for ccRCC tumorigenesis [20–24], as well as miR-185 and miR-221 [23,25].
By using a retrospective cohort of 20 formalin-fixed paraffin-embedded (FFPE) tissue samples,
we evaluated the levels of specific miRNAs differentially expressed in ccRCC vs. matched
normal tissues. We evidenced miR-21-5p and miR-210-3p as the most significantly up-regulated
in this patient cohort, highlighting these onco-miRNAs as possible relevant players involved in
ccRCC carcinogenesis.
2. Results
Among the miRNAs deregulated in several human cancers, we selected four miRNAs
(miR-21-5p, miR-210-3p, miR-185-5p and miR-221-3p) to evaluate their expression in a retrospective
cohort of formalin-fixed paraffin-embedded (FFPE) tissues obtained from 20 ccRCC patients
undergoing surgical nephrectomy resection. The characteristics of ccRCC patients and tumor
specimens are reported in the Patients and Methods section and summarized in Table 1. A total
of 20 matched ccRCC and adjacent normal tissue samples were collected. Interestingly, miR-21-5p
and miR-210-3p resulted significantly up-regulated in ccRCC vs. normal tissues, with a p value of
0.0083 and 0.0010, respectively (Figure 1). miR-185-5p and miR-221-3p, although did not show any
statistically significant modulation between tumor and normal tissues, show a trend of expression
similar to miR-21-5p and miR-210-3p (Figure 1). Moreover, we analyzed miR-145-5p expression that
usually results particularly down-regulated in several tumor samples compared to normal tissues.
We evidenced that miR-145-5p did not show any statistically significant modulation between tumor
and normal tissues.
3. Discussion
In this study we observed that specific miRNAs, previously reported as up-regulated in
ccRCC vs. autologous normal tissues, also show increased expression levels in our series of 20 FFPE
tumor samples relatively to their matched normal counterparts. Specifically, among the up-regulated
miRNAs, we confirmed increased levels of miR-21-5p, miR-210-3p, miR-185-5p and miR-221-3p.
miR-21-5p and miR-210-3p resulted significantly up-regulated in this patient cohort highlighting
these onco-miRNAs as relevant players involved in ccRCC tumorigenesis.
Interestingly, the increased expression of miR-21, miR-210, miR-185, miR-221 was previously
reported in ccRCC patients and their contribution to ccRCC tumorigenesis is currently under
investigation. miR-221 was significantly increased in ccRCC tissues and cell lines, while its
knock-down inhibited cell proliferation, migration and invasion of renal cancer cells [25]. miR-210
was significantly overexpressed in ccRCC relatively to normal kidney and patients with high
levels of miR-210 show a statistically higher incidence of disease recurrence [21]. Moreover,
the down-regulation of miR-210 also reduced the migratory and invasive potential of metastatic
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RCC cells [22]. Using ccRCC and matched normal kidney samples, it was also evidenced that the
increased levels of miR-185 and miR-21 in tumors correlate with the loss of function of specific
tumor suppressors such as PTPN13, SLC12A1 and TCF21 [23]. Noteworthy is that miR-21 not only
shows up-regulated expression in tumor tissues but also its serum levels resulted to be significantly
correlated with the clinical staging of ccRCC patients [26].
In summary, this study confirms the deregulation of specific oncogenic miRNAs in ccRCC tissues
and further supports the potential clinical usefulness of these miRNAs in ccRCC management.
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Figure 1. Evaluation of microRNAs levels in clear cell renal cell carcinoma (ccRCC) patients. Dot 
plots showing the expression of miR-21-5p, miR-210-3p, miR-185-5p and miR-221-3p and miR-145-5p 
in a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissues from 20 ccRCC patients. 
A total of 20 matched ccRCC tumor (T) and adjacent normal tissue (N) samples were analyzed by 
RT-qPCR. The expression value of each miRNA was normalized over the average of RNU66, RNU19 
and SCARNA17 expression. The p value was calculated by using a non-parametric Wilcoxon test 
with paired data and miRNAs whose differential expression was statistically significant (** p < 0.01) 
were indicated. Dot plots with the scatter of the individual data (left panel) or with connected lines 
between matched samples (right panel) are shown. Horizontal lines represent the median 
expression. 
Figure 1. Evaluation of microRNAs levels in clear cell renal cell carcinoma (ccRCC) patients. Dot plots
showing the expression of miR-21-5p, miR-210-3p, miR-185-5p and miR-221-3p and miR-145-5p in
a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissues from 20 ccRCC patients.
A total of 20 matched ccRCC tumor (T) and adjacent normal tissue (N) samples were analyzed by
RT-qPCR. The expression value of each miRNA was normalized over the average of RNU66, RNU19
and SCARNA17 expression. The p value was calculated by using a non-parametric Wilcoxon test
with paired data and miRNAs whose differential expression was statistically significant (** p < 0.01)
were indicated. Dot plots with the scatter of the individual data (left panel) or with connected lines
between matched samples (right panel) are shown. Horizontal lines represent the median expression.
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4. Patients and Methods
4.1. Patients
This study was conducted on a retrospective cohort of ccRCC formalin-fixed paraffin-embedded
(FFPE) tissue samples from 20 patients who underwent surgical resection between October 2011 and
November 2013. For all the patients, FFPE-matched normal peritumoral kidney tissues were also
considered. The patients were not treated with any neo-adjuvant therapy before surgery. Five patients
were female (25%) and 15 patients were male (75%) with a mean age of 68.9 years old and a mean
Body Mass Index (BMI) of 27.4 kg/m2. All the cases presented a clear cell histotype of RCC at the
histological examination. The surgery procedures performed as treatments for these patients were:
(i) open radical nephrectomy in 4 cases (20%); (ii) laparoscopic radical nephrectomy in 12 cases (60%);
(iii) laparoscopic partial nephrectomy in 4 cases (20%). According to the tumor, node, and metastasis
(TNM) classification, 10 patients have been identified as Stage I (50%), 5 patients have been identified
as Stage II (25%), and 5 patients as Stage III (25%). Fuhrman’s grade has also been evaluated with 15%
of cases belonging to the G1 grade (3 patients), 50% of cases belonging to G2 (10 patients) and 30% of
cases to the G3 grade (6 patients). Only 1 patient actually showed a G2/3 grade. Complications have
been classified as well and, according to the Clavien-Dindo classification, they have been identified
only as grade I (75%) and grade II (25% of cases) [27]. Finally, main risk factors (such as hypertension,
obesity and smoking habit) have been considered and findings showed that hypertension affected
9 patients (45%), obesity have been found in 5 (25%), and upon 20 patients, 7 were cigarette smokers;
of the remaining 13 non-smokers, 4 have a history of tabagism (Table 1).
4.2. RNA Extraction and MicroRNA Expression Analysis
RNA from FFPE samples was extracted using the miRneasyr FFPE kit (Qiagen, Chatsworth,
CA, USA) following the manufacturer’s instructions. The concentration and purity of total RNA
were assessed using a Nanodrop TM 1000 spectrophotometer (Nanodrop Technologies, Wilmington,
DE, USA). A quantity of 150 ng of total RNA was reverse transcribed in 8 µL using miScript II
RT kit (Qiagen, Chatsworth) and 1 µL of cDNA dilution (1:4) was used for quantitative real
time PCR (RT-qPCR) experiments. PCR quantification analysis of the SCARNA17 and miRNAs
miR-21-5p, miR-210-3p, miR-185-5p, miR-221-3p and miR-145-5p, was performed using the miScript
SYBR Green PCR kit (Qiagen, Chatsworth) with the miScript Primer Assay Hs-SCARNA17
(#MS00014014), Hs-miR-21-5p (#MS00009079), Hs-miR-210-3p (#MS00003801), Hs-miR-185-5p
(#MS00003647), Hs-miR-221-3p (#MS00003857), Hs-miR-145-5p (#MS00003528) (Qiagen, Chatsworth,
CA, USA).
The expression analyses of RNU19 and RNU66 were performed by TaqMan MicroRNA RT
assay and TaqMan MiRNAr Assays (RNU19 #001003 and RNU66 #001002) (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s protocol.
All reactions were performed in duplicate. Data were analyzed by quantification relatively to a
standard curve. The standard curve was prepared with serial dilutions of a reference cDNA obtained
from RNA extracted from a tumor sample. z-scores were calculated for all expression values to
standardize the data. Subsequently, z-score values of RNU66, RNU19 and SCARNA17 were averaged
and used to normalize the expression values of each miRNA. The p value was calculated by using
a non-parametric Wilcoxon test with paired data and miRNAs whose differential expression was
statistically significant (** p < 0.01) was indicated.
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Table 1. Clinical characteristics of patients with clear cell renal cell carcinoma (ccRCC).
Gender/Age BMI Clavien Hyperten. Smok. Habit Tumor Size Nodal Status Metast. TNM Stage Histology Tumour Cells (%) Grade Surgery
M/65 33.2 II No No T2a Nx Mx II ccRCC 87 G2 O. Rad. Neph
F/65 22.3 I No Yes T1a Nx Mx I ccRCC 89 G2/3 L. Rad. Neph
M/61 25.9 I No Former-15 yrs T2 N0 Mx II ccRCC 90 G3 O. Rad. Neph
M/68 29.9 I Yes Former-30 yrs T3a Nx Mx III ccRCC 84 G3 O. Rad. Neph
M/82 21.9 I No No T3a Nx Mx III ccRCC 86 G3 L. Rad. Neph
M/84 24.6 I No No T2a Nx Mx II ccRCC 87 G2 O. Rad. Neph
M/59 28.4 I Yes Yes T1a Nx Mx I ccRCC 88 G2 L. Part. Neph
M/83 30.7 II No No T1a N0 Mx I ccRCC 90 G2 L. Rad. Neph
M/69 28.3 I Yes No T2b Nx Mx II ccRCC 90 G2 L. Rad. Neph
M/55 23.14 I Yes No T2b Nx Mx II ccRCC 90 G2 L. Rad. Neph
F/72 25.59 I No Yes T1b Nx Mx I ccRCC 88 G2 L. Rad. Neph
M/65 40.3 II No Yes T1a Nx Mx I ccRCC 87 G1 L. Part. Neph
F/59 31.4 I Yes Former-15 yrs T1a Nx Mx I ccRCC 86 G1 L. Part. Neph
M/63 26.5 II No Yes T1b N0 Mx I ccRCC 85 G2 L. Rad. Neph
F/87 22.3 I Yes No T3a N0 Mx III ccRCC 88 G3 L. Rad. Neph
F/56 30.2 II Yes Yes T1a Nx Mx I ccRCC 89 G2 L. Rad. Neph
M/64 24.3 I No No T3a Nx Mx III ccRCC 88 G3 L. Rad. Neph
M/82 26.65 I Yes No T3a Nx Mx III ccRCC 90 G3 L. Rad. Neph
M/77 29.46 I Yes Yes T1a Nx Mx I ccRCC 88 G1 L. Part. Neph
M/66 24.71 I No Former-25 yrs T1a Nx Mx I ccRCC 89 G2 L. Rad. Neph
M: Male; F: Female; BMI: Body Mass Index; Clavien: Clavien-Dindo Classification; Hyperten: Hypertension; Smok. Habit: Smoking Habit; Metast: Metastasis; TNM: Tumor, Node,
and Metastasis Classification; yrs: years; T: Tumor Size; Nx: Regional Lymph Nodes cannot be assessed; N0: No Regional Lymph Node metastasis; Mx: Distant Metastasis cannot be
evaluated; G: Grade; O. Rad. Neph: Open Radical Nephrectomy; L. Rad. Neph: Laparoscopic Radical Nephrectomy; L. Part. Neph: Laparoscopic Partial Nephrectomy.
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